{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:31:49Z","timestamp":1772901109364,"version":"3.50.1"},"reference-count":41,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"6","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004726","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"ontario ministry of health and long-term care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Can Pharm J"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Due to the coronavirus disease 2019 (COVID-19) pandemic, Health Canada issued an exemption to the Controlled Drugs and Substances Act (CDSA) on March 19, 2020, enabling pharmacists to act as prescribers of controlled substances to support continuity of care. Our study investigates utilization of the CDSA exemption by Ontario pharmacists with the intent to inform policy on pharmacist scope of practice and to improve future patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a time-series analysis of pharmacist-prescribed opioid, benzodiazepine and stimulant claims data using Ontario Narcotics Monitoring System (NMS) data between January 2019 and December 2021. We used ARIMA modelling to measure the change to these classes of claims and to opioid claims containing quantities greater than a 30-day supply.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Postexemption, the average weekly number of pharmacist-prescribed opioid, benzodiazepine and stimulant claims rose by 146% (160 to 393 claims\/week), 960% (49 to 515 claims\/week) and 2150% (8 to 177 claims\/week), respectively. There was a 2-week lag period between the time of announcement and the statistically significant increase in claims on April 5, 2020( p &lt; 0.0001). The total number of claims for opioid quantities exceeding a 30-day supply decreased by 60%. Cumulative pharmacist-prescribed claims accounted for under 2% of the total NMS claims.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation:<\/jats:title>\n                    <jats:p>Ontario pharmacists used the CDSA exemption but were prescribing at low rates. These findings suggest an effective change to pharmacy practice as the low rates show pharmacists used the exemption as a last line of defense. This may lead to further studies exploring treatment breaks during the COVID-19 pandemic and future changes to pharmacist scope to benefit patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17151635221126481","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T09:13:28Z","timestamp":1665566008000},"page":"326-333","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of the COVID-19 Controlled Drugs and Substances Act exemption on pharmacist prescribing of opioids, benzodiazepines and stimulants in Ontario: A cross-sectional time-series analysis"],"prefix":"10.3138","volume":"155","author":[{"given":"Ann","family":"Chang","sequence":"first","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanzeh","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"McCormack","sequence":"additional","affiliation":[{"name":"ICES, Toronto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto"},{"name":"Li Ka Shing Knowledge Institute, Unity Health, Toronto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisa","family":"Shivji","sequence":"additional","affiliation":[{"name":"Ontario College of Pharmacists, Toronto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-6129","authenticated-orcid":false,"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto"},{"name":"Women\u2019s College Hospital, Toronto, Ontario"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1696","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"bibr1-17151635221126481","unstructured":"World Health Organization. Listings of WHO\u2019s response to COVID-19. Available: https:\/\/www.who.int\/news\/item\/29-06-2020-covidtimeline (accessed Jan. 20, 2021)."},{"key":"bibr2-17151635221126481","unstructured":"Government of Canada, Department of Justice. Government of Canada\u2019s response to COVID-19. Available: https:\/\/www.justice.gc.ca\/eng\/csj-sjc\/covid.html (accessed Jan. 20, 2021)."},{"key":"bibr3-17151635221126481","unstructured":"Canada Public Health Agency. COVID-19 pandemic guidance for the health care sector. Available: https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/2019-novel-coronavirus-infection\/health-professionals\/covid-19-pandemic-guidance-health-care-sector.html#a3 (accessed Jan. 20, 2021)."},{"key":"bibr4-17151635221126481","unstructured":"Government of Ontario. Report on Ontario\u2019s Provincial Emergency from March 17, 2020 to July 24, 2020. Available: https:\/\/www.ontario.ca\/document\/report-ontarios-provincial-emergency-march-17-2020-july-24-2020 (accessed Jan. 20, 2021)."},{"key":"bibr5-17151635221126481","unstructured":"Canadian Institute for Health Information. Overview: COVID-19\u2019s impact on health care systems. Available: https:\/\/www.cihi.ca\/en\/covid-19-resources\/impact-of-covid-19-on-canadas-health-care-systems\/overview-covid-19s-impact-on (accessed Sept. 11, 2021)."},{"key":"bibr6-17151635221126481","doi-asserted-by":"crossref","unstructured":"Friesen EL, Kurdyak PA, Gomes T, et al. The impact of the COVID-19 pandemic on opioid-related harm in Ontario. Toronto, ON: The Ontario COVID-19 Science Advisory Table; 2021. Available: https:\/\/covid19-sciencetable.ca\/sciencebrief\/the-impact-of-the-covid-19-pandemic-on-opioid-related-harm-in-ontario\/ (accessed Sept. 11, 2021).","DOI":"10.47326\/ocsat.2021.02.42.1.0"},{"key":"bibr7-17151635221126481","unstructured":"Justice Laws. Consolidated federal laws of Canada, Controlled Drugs and Substances Act. Available: https:\/\/laws-lois.justice.gc.ca\/eng\/acts\/C-38.8\/ (accessed Sept. 11, 2021)."},{"key":"bibr8-17151635221126481","unstructured":"Justice Laws. Consolidated federal laws of Canada, benzodiazepines and other targeted substances regulations. Available: https:\/\/laws-lois.justice.gc.ca\/eng\/regulations\/SOR-2000-217\/index.html (accessed Sept. 11, 2021)."},{"issue":"1","key":"bibr9-17151635221126481","volume":"6","author":"Lacasse A","year":"2021","journal-title":"Pain Rep"},{"key":"bibr10-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2019.158492"},{"key":"bibr11-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103644"},{"key":"bibr12-17151635221126481","unstructured":"Health Canada. Exemptions for practitioners and pharmacists prescribing and providing controlled substances and for patients, during the coronavirus pandemic. Available: https:\/\/www.canada.ca\/en\/health-canada\/services\/health-concerns\/controlled-substances-precursor-chemicals\/policy-regulations\/policy-documents\/section-56-1-class-exemption-patients-pharmacists-practitioners-controlled-substances-covid-19-pandemic.html#shr-pg0 (accessed Jan. 12, 2021)."},{"key":"bibr13-17151635221126481","unstructured":"Canadian Pharmacists Association. COVID-19 and controlled drugs and substances. 2020. Available: https:\/\/www.pharmacists.ca\/cpha-ca\/assets\/File\/cpha-on-the-issues\/CovidCDSA.pdf (accessed May 6, 2022)."},{"key":"bibr14-17151635221126481","unstructured":"Ontario College of Pharmacists. Initiating, adapting and renewing prescriptions. Available: https:\/\/www.ocpinfo.com\/regulations-standards\/practice-policies-guidelines\/adapting-renewing-prescriptions\/ (accessed Jan. 17, 2021)."},{"key":"bibr15-17151635221126481","unstructured":"Ontario College of Pharmacists. Prescription Regulation Summary Chart, March 2020. Available: https:\/\/www.ocpinfo.com\/wp-content\/uploads\/2019\/05\/Prescription-Regulation-Summary-Chart-Summary-of-Laws.pdf (accessed Apr. 2, 2021)."},{"key":"bibr16-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1177\/1715163518805509"},{"issue":"6","key":"bibr17-17151635221126481","volume":"148","author":"Faruquee CF","year":"2015","journal-title":"Can Pharm J (Ott)"},{"key":"bibr18-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1186\/s12199-020-00891-4"},{"key":"bibr19-17151635221126481","volume":"23","author":"Shah S","year":"2020","journal-title":"Pain Physician"},{"key":"bibr20-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000753"},{"key":"bibr21-17151635221126481","unstructured":"Canadian Institute for Health Information. Overview: COVID-19\u2019s impact on health care systems. Available: https:\/\/www.cihi.ca\/en\/covid-19-resources\/impact-of-covid-19-on-canadas-health-care-systems\/overview-covid-19s-impact-on (accessed Sept. 11, 2021)."},{"key":"bibr22-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2020.07.003"},{"key":"bibr23-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109303"},{"key":"bibr24-17151635221126481","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.2980"},{"key":"bibr25-17151635221126481","unstructured":"Ministry of Health. Ontario drug programs reference manual. Available: https:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/resources\/odp_reference_manual.pdf (accessed Sept. 13, 2021)."},{"key":"bibr26-17151635221126481","unstructured":"ICES. Working with ICES data. Available: https:\/\/www.ices.on.ca\/Data-and-Privacy\/ICES-data\/Working-with-ICES-Data (accessed Sept. 13, 2021)."},{"key":"bibr27-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.12.018"},{"key":"bibr28-17151635221126481","unstructured":"Government of Ontario Ministry of Health and Long-term Care. Pharmaceutical Opinion Program. Available: https:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/pharmaopinion\/ (accessed Sept. 14, 2021)."},{"key":"bibr29-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1136\/bmjoq-2019-000635"},{"key":"bibr30-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz204"},{"key":"bibr31-17151635221126481","unstructured":"Ontario College of Pharmacists. Medical Directives and the Delegation of Controlled Acts. Available: https:\/\/www.ocpinfo.com\/regulations-standards\/practice-policies-guidelines\/medical-directives\/ (accessed Sept. 13, 2021)."},{"key":"bibr32-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.202303"},{"key":"bibr33-17151635221126481","first-page":"1","volume":"21","author":"Hayden JC","year":"2020","journal-title":"Ir J Psychol Med"},{"key":"bibr34-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1177\/17151635211034530"},{"key":"bibr35-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050223"},{"key":"bibr36-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2020.03.015"},{"key":"bibr37-17151635221126481","unstructured":"Centre for Addiction and Mental Health (CAMH). Modifications to opioid agonist treatment Delivery\u2014March 22, 2020. Available: https:\/\/www.camh.ca\/en\/health-info\/mental-illness-and-addiction-index\/methadone (accessed Sept. 14, 2021)"},{"key":"bibr38-17151635221126481","unstructured":"Notice: Ontario Drug Benefit (ODB) Program Changes and Guidance for Dispensers during the COVID-19 Public Health Emergency. Ontario Ministry of Health. Available: https:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/opdp_eo\/notices\/exec_office_20200320.pdf (accessed Aug. 21, 2021)."},{"key":"bibr39-17151635221126481","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2016.01.002"},{"issue":"6","key":"bibr40-17151635221126481","volume":"148","author":"Faruquee CF","year":"2015","journal-title":"Can Pharm J (Ott)"},{"key":"bibr41-17151635221126481","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S99540"}],"container-title":["Canadian Pharmacists Journal \/ Revue des Pharmaciens du Canada"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17151635221126481","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17151635221126481","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17151635221126481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:06:51Z","timestamp":1772834811000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/17151635221126481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1177\/17151635221126481"],"URL":"https:\/\/doi.org\/10.1177\/17151635221126481","relation":{},"ISSN":["1715-1635","1913-701X"],"issn-type":[{"value":"1715-1635","type":"print"},{"value":"1913-701X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]}}}